Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
BioCryst Pharmaceuticals
Biotech
BMS vet answers Foghorn’s call for CBO—Chutes & Ladders
BMS vet answers Foghorn’s call for CBO. Orbital charges up with former Spark CEO. CellCentric secures first CDO.
Darren Incorvaia
,
Zoey Becker
,
Gabrielle Masson
Sep 6, 2024 8:30am
45 days later, BioCryst abandons another drug, citing competition
Dec 15, 2022 10:29am
BioCryst leaves ultra-rare disease efforts in hands of peers
Nov 1, 2022 10:00am
BioCryst's voluntary pause turns into partial FDA hold
May 5, 2022 11:11am
In just 72 words, BioCryst pauses enrollment for for 3 trials
Apr 8, 2022 10:48am
BioCryst starts COVID-19 trial of broad-spectrum antiviral
Apr 10, 2020 7:55am